Research & Literature

Applying the ACR/EULAR Systemic Sclerosis Classification Criteria to the Spanish Scleroderma Registry Cohort.

Sáez-Comet L, Simeón-Aznar CP, Pérez-Conesa M, et al.

The Journal of rheumatology 2015; (42(12)):2327-31 doi:10.3899/jrheum.150144.

Early Cardiovascular Disease After the Diagnosis of Systemic Sclerosis.

Aviña-Zubieta JA, Man A, Yurkovich M, et al.

The American journal of medicine 2016; (129(3)):324-31.

Caring for the Patient With Limited Systemic Scleroderma.

Lachner KD

Orthopedic nursing 2016; (35(1)):5-10; quiz 11-2 doi:10.1097/NOR.0000000000000212.

Paraneoplastic Scleroderma: Are There Any Clues?

Jedlickova H, Durčanská V, Vašků V

Acta dermatovenerologica Croatica : ADC 2016; (24(1)):78-80.

Lung and gastrointestinal complications are leading causes of death in SCORE, a multi-ethnic Singapore systemic sclerosis cohort.

Santosa A, Tan CS, Teng GG, et al.

Scandinavian journal of rheumatology 2016; (45(6)):499-506 doi:10.3109/03009742.2016.1153141.

Validation of the 2013 American College of Rheumatology/European League Against Rheumatism classification criteria for systemic sclerosis in patients from a capillaroscopy clinic.

Melchor S, Joven BE, Andreu JL, et al.

Seminars in arthritis and rheumatism 2016; (46(3)):350-355 doi:10.1016/j.semarthrit.2016.05.007.

Review: Frontiers of Antifibrotic Therapy in Systemic Sclerosis.

Distler JH, Feghali-Bostwick C, Soare A, et al.

Arthritis & rheumatology (Hoboken, N.J.) 2017; (69(2)):257-267 doi:10.1002/art.39865.

Should we look for anti-RNA polymerase III antibodies in systemic sclerosis patients with anti-centromere or anti-topoisomerase I antibodies?

Benyamine A, Bertin D, Heim X, et al.

European journal of internal medicine 2017; (44()):e42-e44 doi:10.1016/j.ejim.2017.07.033.

European Dermatology Forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromes.

Knobler R, Moinzadeh P, Hunzelmann N, et al.

Journal of the European Academy of Dermatology and Venereology : JEADV 2017; (31(9)):1401-1424 doi:10.1111/jdv.14458.

Validation of the ACR/EULAR classification criteria for systemic sclerosis in patients with early scleroderma.

Araújo FC, Camargo CZ, Kayser C

Rheumatology international 2017; (37(11)):1825-1833 doi:10.1007/s00296-017-3787-1.

Efficacy and Safety of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis: A Randomized, Placebo-Controlled, Phase II Study.

Denton CP, Hachulla É, Riemekasten G, et al.

Arthritis & rheumatology (Hoboken, N.J.) 2017; (69(12)):2370-2379 doi:10.1002/art.40242.

Scleroderma Renal Crisis in a Normotensive Patient.

Asamoah-Odei E

Kidney international reports 2016; (1(4)):311-315 doi:10.1016/j.ekir.2016.07.005.

Occupational Therapy Treatment to Improve Upper Extremity Function in Individuals with Early Systemic Sclerosis: A Pilot Study.

Murphy SL, Barber MW, Homer K, et al.

Arthritis care & research 2018; (70(11)):1653-1660 doi:10.1002/acr.23522.

The Role of Oxidative Stress in the Development of Systemic Sclerosis Related Vasculopathy.

Abdulle AE, Diercks GFH, Feelisch M, et al.

Frontiers in physiology 2018; (9()):1177 doi:10.3389/fphys.2018.01177.

African Americans and Scleroderma: Examining the Root Cause of the Association.

Morgan ND, Gelber AC

Arthritis care & research 2019; (71(9)):1151-1153 doi:10.1002/acr.23860.

The role of nailfold videocapillaroscopy in patients with systemic sclerosis.

Kubo S, Smith V, Cutolo M, Tanaka Y

Immunological medicine 2018; (41(3)):113-119 doi:10.1080/25785826.2018.1531189.

[Systemic sclerosis-clinical picture, diagnosis, and treatment].

Becker MO, Distler O, Maurer B

Zeitschrift fur Rheumatologie 2019; (78(5)):439-457 doi:10.1007/s00393-019-0639-2.

[Sclerosing skin diseases].

Sticherling M

Der Internist 2019; (60(8)):783-791 doi:10.1007/s00108-019-0643-2.

Systemic sclerosis - the dermatological perspective.

Sticherling M

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 2019; (17(7)):716-728 doi:10.1111/ddg.13887.

Systemic sclerosis.

Hughes M, Herrick AL

British journal of hospital medicine (London, England : 2005) 2019; (80(9)):530-536 doi:10.12968/hmed.2019.80.9.530.

Systemic Sclerosis Associated Interstitial Lung Disease: New Directions in Disease Management.

Mirsaeidi M, Barletta P, Glassberg MK

Frontiers in medicine 2019; (6()):248 doi:10.3389/fmed.2019.00248.

[Treatment of systemic sclerosis-associated interstitial lung disease].

Prasse A, Bonella F, Müller-Ladner U, et al.

Zeitschrift fur Rheumatologie 2020; (79(3)):294-303 doi:10.1007/s00393-019-00724-y.

Characteristics of patients with systemic sclerosis living in Qatar.

Alam F, Abdulaziz HM, Ul Haq I, et al.

Qatar medical journal 2019; (2019(3)):16 doi:10.5339/qmj.2019.16.

Autologous stem cell transplantation for progressive systemic sclerosis: a prospective non-interventional study from the European Society for Blood and Marrow Transplantation Autoimmune Disease Working Party.

Henes J, Oliveira MC, Labopin M, et al.

Haematologica 2021; (106(2)):375-383 doi:10.3324/haematol.2019.230128.

ACE inhibitors in SSc patients display a risk factor for scleroderma renal crisis-a EUSTAR analysis.

Bütikofer L, Varisco PA, Distler O, et al.

Arthritis research & therapy 2020; (22(1)):59 doi:10.1186/s13075-020-2141-2.

Nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease.

Yamasaki Y, Kuwana M

Expert review of clinical immunology 2020; (16(6)):547-560 doi:10.1080/1744666X.2020.1777857.

Renal Involvement in Systemic Sclerosis: An Update.

Chrabaszcz M, Małyszko J, Sikora M, et al.

Kidney & blood pressure research 2020; (45(4)):532-548 doi:10.1159/000507886.

The adoption of nintedanib in systemic sclerosis: the SENSCIS study.

Bruni T, Varone F

Breathe (Sheffield, England) 2020; (16(2)):200005 doi:10.1183/20734735.0005-2020.

An Update on Systemic Sclerosis and its Perioperative Management.

Carr ZJ, Klick J, McDowell BJ, et al.

Current anesthesiology reports 2020; (10(4)):512-521 doi:10.1007/s40140-020-00411-8.

Refractory scleroderma renal crisis precipitated after high-dose oral corticosteroids and concurrent intravitreal injection of bevacizumab.

Hanna RM, Abdelnour L, Zuckerman JE, et al.

SAGE open medical case reports 2020; (8()):2050313X20952650 doi:10.1177/2050313X20952650.

Hematopoietic stem cell transplantation for systemic sclerosis: Brazilian experience.

Henrique-Neto Á, Vasconcelos MYK, Dias JBE, et al.

Advances in rheumatology (London, England) 2021; (61(1)):9 doi:10.1186/s42358-021-00166-8.

Time for precision medicine in systemic sclerosis-associated pulmonary arterial hypertension.

Launay D, Sanges S, Sobanski V

The European respiratory journal 2021; (57(6)) doi:10.1183/13993003.00205-2021.

Clinical trial protocol: PRednisolone in early diffuse cutaneous Systemic Sclerosis (PRedSS).

Herrick AL, Griffiths-Jones DJ, Ryder WD, et al.

Journal of scleroderma and related disorders 2021; (6(2)):146-153 doi:10.1177/2397198320957552.

French recommendations for the management of systemic sclerosis.

Hachulla E, Agard C, Allanore Y, et al.

Orphanet journal of rare diseases 2021; (16(Suppl 2)):322 doi:10.1186/s13023-021-01844-y.

A comprehensive framework for navigating patient care in systemic sclerosis: A global response to the need for improving the practice of diagnostic and preventive strategies in SSc.

Saketkoo LA, Frech T, Varjú C, et al.

Best practice & research. Clinical rheumatology 2021; (35(3)):101707 doi:10.1016/j.berh.2021.101707.

Healthcare utilization and economic burden in systemic sclerosis: a systematic review.

Martin Calderon L, Chaudhary M, Pope JE

Rheumatology (Oxford, England) 2022; (61(8)):3123-3131 doi:10.1093/rheumatology/keab847.

Early diagnosis of systemic sclerosis, where do we stand today?

Lepri G, Bellando Randone S, Matucci Cerinic M, Guiducci S

Expert review of clinical immunology 2022; (18(1)):1-3 doi:10.1080/1744666X.2022.2015327.

Interstitial lung disease in Indonesian adult with systemic sclerotic: A rare case.

Anggoro A, Hasan H

Annals of medicine and surgery (2012) 2022; (75()):103386 doi:10.1016/j.amsu.2022.103386.

Phenotype of limited cutaneous systemic sclerosis patients with positive anti-topoisomerase I antibodies: data from the EUSTAR cohort.

Zanatta E, Huscher D, Ortolan A, et al.

Rheumatology (Oxford, England) 2022; (61(12)):4786-4796 doi:10.1093/rheumatology/keac188.

Combination therapy with bosentan and sildenafil for refractory digital ulcers and Raynaud's phenomenon in a 30-year-old woman with systemic sclerosis: Case report and literature review.

Rademacher JG, Wincup C, Tampe B, Korsten P

Journal of scleroderma and related disorders 2020; (5(2)):159-164 doi:10.1177/2397198319876738.

Kidney involvement in systemic sclerosis: From pathogenesis to treatment.

Bruni C, Cuomo G, Rossi FW, et al.

Journal of scleroderma and related disorders 2018; (3(1)):43-52 doi:10.1177/2397198318758607.

Management of Raynaud's phenomenon in systemic sclerosis-a practical approach.

Fernández-Codina A, Cañas-Ruano E, Pope JE

Journal of scleroderma and related disorders 2019; (4(2)):102-110 doi:10.1177/2397198318823951.

Patient perception of disease burden in diffuse cutaneous systemic sclerosis.

Khanna D, Allanore Y, Denton CP, et al.

Journal of scleroderma and related disorders 2020; (5(1)):66-76 doi:10.1177/2397198319866615.

Rituximab on lung, skin, and joint involvement in patients with systemic sclerosis: A case series study and review of the literature.

Yarkan Tuğsal H, Zengin B, Kenar G, et al.

International journal of rheumatic diseases 2022; (25(7)):755-768 doi:10.1111/1756-185X.14333.

Nailfold capillaroscopy for the early diagnosis of the scleroderma spectrum of diseases in patients without Raynaud's phenomenon.

Hong C, Xiang L, Saffari SE, Low AH

Journal of scleroderma and related disorders 2022; (7(2)):144-150 doi:10.1177/23971983221088460.

Autoantibodies as Biomarker and Therapeutic Target in Systemic Sclerosis.

Graßhoff H, Fourlakis K, Comdühr S, Riemekasten G

Biomedicines 2022; (10(9)) doi:10.3390/biomedicines10092150.

Centromere defects, chromosome instability, and cGAS-STING activation in systemic sclerosis.

Paul S, Kaplan MH, Khanna D, et al.

Nature communications 2022; (13(1)):7074 doi:10.1038/s41467-022-34775-8.

Systemic sclerosis.

Volkmann ER, Andréasson K, Smith V

Lancet (London, England) 2023; (401(10373)):304-318 doi:10.1016/S0140-6736(22)01692-0.

Comparing clinical characteristics of systemic sclerosis with or without interstitial lung disease: A cross-sectional study from a single center of the Chinese Rheumatism Data Center.

Li H, Zhang X, Yu L, et al.

Frontiers in medicine 2022; (9()):1061738 doi:10.3389/fmed.2022.1061738.

The Gut Microbial Metabolite Trimethylamine N-Oxide is Linked to Specific Complications of Systemic Sclerosis.

Stec A, Maciejewska M, Paralusz-Stec K, et al.

Journal of inflammation research 2023; (16()):1895-1904 doi:10.2147/JIR.S409489.

Comprehensive description of the prevalence, serological and clinical characteristics, and visceral involvement of systemic sclerosis (scleroderma) in a large cohort from the United Arab Emirates Systemic Sclerosis Registry.

Namas R, Elarabi M, Khan S, et al.

Journal of scleroderma and related disorders 2023; (8(2)):137-150 doi:10.1177/23971983221145788.

Cutaneous Manifestations, Clinical Characteristics, and Prognosis of Patients With Systemic Sclerosis Sine Scleroderma: Data From the International EUSTAR Database.

Lescoat A, Huang S, Carreira PE, et al.

JAMA dermatology 2023; (159(8)):837-847 doi:10.1001/jamadermatol.2023.1729.

Self-Reported Systemic Sclerosis-Related Symptoms Are More Prevalent in Subjects with Raynaud's Phenomenon in the Lifelines Population: Focus on Pulmonary Complications.

van de Zande SC, Abdulle AE, Al-Adwi Y, et al.

Diagnostics (Basel, Switzerland) 2023; (13(13)) doi:10.3390/diagnostics13132160.

Thrombotic Microangiopathy and Multiple Organ Failure in Scleroderma Renal Crisis: A Case Report.

Aterini L, Gallo M, Vadalà B, Aterini S

Cureus 2023; (15(8)):e44322 doi:10.7759/cureus.44322.

Systemic sclerosis sine scleroderma with atypical clinical course: a rare case report.

Samha R, Ghaddar SA, Raya M, Alhadi SA

Annals of medicine and surgery (2012) 2023; (85(11)):5656-5661 doi:10.1097/MS9.0000000000001266.

Stratification in systemic sclerosis according to autoantibody status versus skin involvement: a study of the prospective EUSTAR cohort.

Elhai M, Sritharan N, Boubaya M, et al.

The Lancet. Rheumatology 2022; (4(11)):e785-e794 doi:10.1016/S2665-9913(22)00217-X.

[The arguments favoring autologous haematopoietic stem cell transplantation in systemic scleroderma].

Pugnet G

La Revue de medecine interne 2024; (45(2)):104-108 doi:10.1016/j.revmed.2024.01.003.

Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial.

Ebata S, Yoshizaki A, Oba K, et al.

The Lancet. Rheumatology 2021; (3(7)):e489-e497 doi:10.1016/S2665-9913(21)00107-7.

Pain levels and associated factors in the Scleroderma Patient-centered Intervention Network (SPIN) cohort: a multicentre cross-sectional study.

Lee YC, Fox RS, Kwakkenbos L, et al.

The Lancet. Rheumatology 2021; (3(12)):e844-e854 doi:10.1016/S2665-9913(21)00318-0.

Exploratory clinical subgroup clustering in systemic sclerosis: Results from the Indian Progressive Systemic Sclerosis Registry.

Philip SS, Janardana R, Shenoy P, et al.

Journal of scleroderma and related disorders 2024; (9(1)):29-37 doi:10.1177/23971983231215470.

[High anti-topoisomerase-1 autoantibodies levels are associated with the extension of skin fibrosis and vascular progression in patients with systemic sclerosis].

Dol C, Granel B, Resseguier N, et al.

La Revue de medecine interne 2024; (45(3)):126-131 doi:10.1016/j.revmed.2023.11.006.

Autoantibodies Targeting G-Protein-Coupled Receptors: Pathogenetic, Clinical and Therapeutic Implications in Systemic Sclerosis.

Binda M, Moccaldi B, Civieri G, et al.

International journal of molecular sciences 2024; (25(4)) doi:10.3390/ijms25042299.

Raynaud's phenomenon associated with psoriatic arthritis.

Che Rahim MJ, Lim JA, Wan Ghazali WS

BMJ case reports 2024; (17(3)) doi:10.1136/bcr-2023-258215.

Spectrum of renal disease in scleroderma other than scleroderma renal crisis: A review of the literature.

Farrukh L, Steen V, Shapiro L, et al.

Clinical nephrology 2024; (102(2)):97-106 doi:10.5414/CN111243.

Scleroderma and scleroderma-like syndromes.

Romanowska-Próchnicka K, Dziewit M, Lesiak A, et al.

Frontiers in immunology 2024; (15()):1351675 doi:10.3389/fimmu.2024.1351675.

Is anticoagulative therapy in systemic sclerosis to be reconsidered?

Marongiu F, Ruberto MF, Barcellona D

Journal of scleroderma and related disorders 2024; (9(2)):81-85 doi:10.1177/23971983241256250.

2023 Brazilian Society of Rheumatology guidelines for the treatment of systemic sclerosis.

Kayser C, de Oliveira Delgado SM, Zimmermann AF, et al.

Advances in rheumatology (London, England) 2024; (64(1)):52 doi:10.1186/s42358-024-00392-w.

The Effect of Telerehabilitation-Based Self-Management Programme on Individuals With Scleroderma.

Karakuş E, Sari F, Avanoğlu Güler A, et al.

Musculoskeletal care 2024; (22(4)):e1947 doi:10.1002/msc.1947.

Autoantibodies in systemic sclerosis overlap syndrome and their correlation with organ damage and survival.

Wang F, Li C, Li X, et al.

Annals of medicine 2024; (56(1)):2407526 doi:10.1080/07853890.2024.2407526.

Systemic sclerosis-associated interstitial lung disease: How to manage in 2024?

Bautista-Sanchez R, Khanna D

Rheumatology and immunology research 2024; (5(3)):157-165 doi:10.2478/rir-2024-0022.

Results from the international collaborative systematic literature review informing the 2023 EULAR recommendations for the treatment of systemic sclerosis.

Lescoat A, Bertoldo E, Čolić J, et al.

Annals of the rheumatic diseases 2024; doi:10.1136/ard-2024-226429.

Fibrosis mechanisms in systemic sclerosis and new potential therapies.

Barile R, Rotondo C, Rella V, et al.

Postgraduate medical journal 2025; (101(1198)):680-689 doi:10.1093/postmj/qgae169.

EULAR recommendations for the treatment of systemic sclerosis: 2023 update.

Del Galdo F, Lescoat A, Conaghan PG, et al.

Annals of the rheumatic diseases 2025; (84(1)):29-40 doi:10.1136/ard-2024-226430.

Systemic sclerosis complicated by azathioprine-induced iatrogenic immunodeficiency-associated lymphoproliferative disorder: A case report.

Okazaki R, Inui G, Funaki Y, et al.

Modern rheumatology case reports 2025; (9(2)) doi:10.1093/mrcr/rxaf017.

Spectrum of Clinical Manifestations in Patients of Scleroderma and Correlation between Cutaneous and Pulmonary Involvement.

Oak J, Unavane O, Mathur R

The Journal of the Association of Physicians of India 2025; (73(3)):17-20 doi:10.59556/japi.73.0855.

Gastroesophageal Intussusception Treated With Combined Transoral Incisionless Fundoplication in a Patient With Systemic Sclerosis.

Memon A, Dugan N, Muniraj T, et al.

ACG case reports journal 2025; (12(4)):e01632 doi:10.14309/crj.0000000000001632.

Correlation Between the Peak of Skin Thickness Progression Rate and Onset of Cardiopulmonary Involvement in Thai Systemic Sclerosis Patients.

Rujirawinitchai P, Foocharoen C, Mahakkanukrauh A, et al.

Journal of clinical medicine 2025; (14(7)) doi:10.3390/jcm14072281.

Rituximab in systemic sclerosis-associated interstitial lung disease: A systematic review and meta-analysis.

Jang JH, Her M, Oh JH, et al.

Science progress 2025; (108(2)):368504251333912 doi:10.1177/00368504251333912.

A review of recent studies on the pathogenesis of Systemic Sclerosis: focus on fibrosis pathways.

Jimenez SA, Mendoza FA, Piera-Velazquez S

Frontiers in immunology 2025; (16()):1551911 doi:10.3389/fimmu.2025.1551911.

Systemic sclerosis and scleroderma renal crisis in African American patients.

Kotamarti R, Hackshaw KV

Journal of the National Medical Association 2025; (117(3)):179-184 doi:10.1016/j.jnma.2025.04.006.

Frequency and determinants of use of immunosuppressants in the Australian Scleroderma Cohort Study.

Fairley JL, Hansen D, Proudman S, et al.

Journal of scleroderma and related disorders 2025; (10(3)):311-321 doi:10.1177/23971983251342690.

Patient-reported gastrointestinal involvement is associated with reduced quality of life and disability in systemic sclerosis.

Kéringer P, Kovács KT, Nagy G, et al.

Journal of scleroderma and related disorders 2025; 23971983251345284 doi:10.1177/23971983251345284.

New horizons in systemic sclerosis treatment: advances and emerging therapies in 2025.

Sieiro Santos C, Del Galdo F

RMD open 2025; (11(3)) doi:10.1136/rmdopen-2025-005776.

The serum levels of specific autoantibodies in systemic sclerosis predict a more severe skin involvement.

Dengler H, Vonow-Eisenring M, Becker MO, et al.

Journal of scleroderma and related disorders 2025; 23971983251357991 doi:10.1177/23971983251357991.

[From renal crisis to lung fibrosis - systemic sclerosis in the course of time].

Jahns KM, Dreher M, Triantafyllias K, et al.

Deutsche medizinische Wochenschrift (1946) 2025; (150(16)):975-979 doi:10.1055/a-2615-9127.

Esophageal dysmotility in systemic sclerosis: Relationship with extra-gastrointestinal manifestations and complementary utility of thoracic imaging.

Santos I, Marques-Gomes C, Diz-Lopes M, et al.

Journal of scleroderma and related disorders 2025; 23971983251362586 doi:10.1177/23971983251362586.

The fibrosis puzzle of systemic sclerosis-associated ILD and the quest for targeted interventions.

Doskaliuk B, Zaiats L, Sahan N, et al.

Therapeutic advances in respiratory disease 2025; (19()):17534666251366023 doi:10.1177/17534666251366023.

Treatment recommendations for the systemic pharmacological treatment of systemic sclerosis digital ulcers: Results from the World Scleroderma Foundation Ad Hoc Committee.

Maltez N, Ross L, Baron M, et al.

Journal of scleroderma and related disorders 2025; 23971983251340559 doi:10.1177/23971983251340559.

Decoding vascular dysfunction in systemic sclerosis: from endothelial damage to clinical implications.

Massay R, Zahn C, Tsou PS

Current opinion in rheumatology 2025; (37(6)):373-383 doi:10.1097/BOR.0000000000001126.

Real-world treatment for systemic sclerosis and systemic sclerosis-associated interstitial lung disease: information from a Japanese hospital claims database.

Funatogawa T, Mii K, Kojima K, et al.

Modern rheumatology 2025; (36(1)):39-48 doi:10.1093/mr/roaf082.

Pain and fatigue in systemic sclerosis: Practical strategies for non-pharmacological management.

Bonomi F, El Aoufy K, Bellando Randone S, et al.

Journal of scleroderma and related disorders 2025; 23971983251369577 doi:10.1177/23971983251369577.

Are systemic sclerosis and localized scleroderma (morphea) part of a common disease spectrum? A systematic review on their coexistence.

De Rosa C, Di Marco G, Bottino V, et al.

Clinics in dermatology 2025; (43(6)):850-858 doi:10.1016/j.clindermatol.2025.09.032.

Systemic Sclerosis-Associated ILD: Insights and Limitations of ScleroID.

Niță C, Groșeanu L

Diagnostics (Basel, Switzerland) 2026; (16(1)) doi:10.3390/diagnostics16010158.

Prevalence and severity of complicated Raynaud's phenomenon in limited and diffuse systemic sclerosis: a multicenter study in Iraq.

Jaafar F, Moayad Z, Gorial F, Alkazzaz A

Reumatologia 2025; (63(6)):383-388 doi:10.5114/reum/207625.

Assessing digital vasculopathy in systemic sclerosis.

Herrick AL

Rheumatology (Oxford, England) 2026; (65(2)) doi:10.1093/rheumatology/keag081.